패밀리 core · Payload core · SMILES 확보
Exploration Score · catalog ranks
Rule-based Catalog Exploration Score for pharmacophore cores and drug/derivative nodes. Not an efficacy prediction.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
Core structure exploration tiers
Rule-based Catalog Exploration Score from SMILES similarity, approved/clinical tags, family network size, and SAR metadata. It does not predict efficacy, safety, or development success.
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.
How similarity is calculated · How clustering works · How exploration priority is scored
치료 영역 · 계열
MedMedium exploration priority2
Upper-mid Exploration Score percentile (X-A bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | MMAE MMAE (auristatin) payload family · Payload | ADC payload | 66 | 패밀리 core · Payload core · SMILES 확보 | |
| Med | SG3199 PBD dimer ADC payload family · Payload | ADC payload | 65 | 패밀리 core · Payload core · SMILES 확보 |
패밀리 core · Payload core · SMILES 확보
MedMedium exploration priority2
Mid-pool Exploration Score (X-B bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Med | Duocarmycin SA Duocarmycin CPI ADC payload series · Payload | ADC payload | 63 | 패밀리 core · Payload core · SMILES 확보 | |
| Med | MMAF MMAE (auristatin) payload family · Payload | ADC payload | 44 | Payload core · SMILES 확보 |
패밀리 core · Payload core · SMILES 확보
Payload core · SMILES 확보
LowLow exploration priority3
Lower Exploration Score — still listed for inspection (X-C bin)
| High exploration priority | 2D | Structure | Class | Exploration Score | Factors |
|---|---|---|---|---|---|
| Low | Tesirine PBD dimer ADC payload family · Payload | ADC payload | 43 | Payload core · SMILES 확보 | |
| Low | Seco-duocarmycin Duocarmycin CPI ADC payload series · Payload | ADC payload | 41 | Payload core · SMILES 확보 | |
| Low | Val-Cit MMAE (auristatin) payload family · Linker | ADC payload | 36 | Linker hub · SMILES 확보 |
Actual weights, formula and input limits
Exploration score method
StructureMoa ranks are a rule-based Exploration Score. An LLM does not predict activity or efficacy. Role, SMILES, and relation signals inside each family are summed and cut into High / Medium / Low exploration priority.
Core tab
- scaffold / payload / linker role weights
- family center-compound bonus
- SMILES source (db · known · pubchem · inherited)
- relation-edge count and derived-child count
Derivative tab
- drug / derivative / adc candidates
- similarity to family center via Morgan fingerprint, radius 2, 2048 bits, Tanimoto
- Approval, clinical and lead tag bonuses have been removed.
Explore tab
- sparse SAR, cross-scaffold pairs, expansion leaves
- weakly linked nodes and catalog-coverage gaps
- relation graph + stored Morgan fingerprints
- category filters
Exploration-priority bins
- High (X-S): top ~12%
- Medium (X-A/X-B): ~12–62%
- Low (X-C): remainder (pools under 5 compounds stay Medium)
Internal exploration metric based on catalog and structural signals. Not a prediction of efficacy, safety, potency, or development success.
평가 시각: 2026. 10. 28. 오후 9:49:28 · 캐시 5분 · 전체 패밀리